NEW YORK, June 19, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company") (NasdaqCM: NWBO). The investigation focuses on whether the Company and its executives violated federal securities laws.
On June 19, 2014, shares of the Company fell during intraday trading $2.06 or 22.97% to trade at $6.91 after a report published by the website TheStreet.com states that, "The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct." MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics.
If you are aware of any facts relating to this investigation, or purchased shares of Northwest Biotherapeutics, you can assist this investigation by contacting either Edward N. Gewirtz or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Edward N. Gewirtz or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC